| Japanese |
|---|
| Title | 心筋脂肪酸代謝イメージング剤β-メチル-p-(123I)-ヨードフェニルペンタデカン酸注射液の第3相臨床試験 - 多施設による有効性と安全性の検討 - |
|---|
| Subtitle | 原著 |
|---|
| Authors | 鳥塚莞爾*, 米倉義晴**, 西村恒彦***, 大嶽達****, 分校久志*****, 玉木長良**, 植原敏勇*** |
|---|
| Authors(kana) | |
|---|
| Organization | *福井医科大学, **京都大学医学部核医学科, ***国立循環器病センター放射線診療部, ****東京大学医学部放射線科, *****金沢大学医学部核医学科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 29 |
|---|
| Number | 4 |
|---|
| Page | 413-433 |
|---|
| Year/Month | 1992/4 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」心疾患患者587例を対象に脂肪酸代謝イメージング剤β-メチル-p-ヨード(123I)フェニルペンタデカン酸の有効性と安全性を検討した. 虚血性心疾患の63%, 心筋症の39%およびその他の心疾患の36%で本剤は201Tlより相対的に著しい集積低下を示した. 心筋梗塞の血行再建術成功例では未施行例に比し本剤の方が201Tlより著しい集積低下(B型)を示す症例が多く, 発症後または術後日数の経過とともに両薬剤の所見が一致する(E型)症例が増加した. 201Tlの再分布領域ではB型が, 固定性欠損領域ではE型が多く, また, 本剤の心筋集積程度は201Tl検査で判定された心筋viabilityとの相関がみられた. 拡張型および二次性心筋症ではE型が約60%に, 弁膜性心疾患や心筋炎ではB型が約45%の症例でみられ, また, 肥大型心筋症や高血圧心ではさまざまな両薬剤の所見の乖離がみられた. 本剤は安全性に問題はなく, 心筋脂肪酸代謝を反映する有効な心疾患診断薬剤であると考えられた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | β-methyl-p-iodophenyl-pentadecanoic acid (123I-BMIPP), Myocardial fatty acid metabolism, Viability, Phase 3 study, Clinical usefulness. |
|---|
| English |
|---|
| Title | Phase 3 Study of β-Methyl-p-(123I)-Iodophenyl-Pentadecanoic Acid, a Myocardial Imaging Agent for Evaluating Fatty Acid Metabolism - A Multi-Center Trial - |
|---|
| Subtitle | Original Article |
|---|
| Authors | Kanji TORIZUKA*, Yoshiharu YONEKURA**, Tsunehiko NISHIMURA***, Tohru OHTAKE****, Hisashi BUNKO*****, Nagara TAMAKI**, Toshiisa UEHARA*** |
|---|
| Authors(kana) | |
|---|
| Organization | *Fukui Medical School, **Department of Nuclear Medicine, Faculty of Medicine, Kyoto University, ***Department of Radiology, National Cardiovascular Center, ****Department of Radiology, Faculty of Medicine, University of Tokyo, *****Department of Nuclear Medicine, School of Medicine, Kanazawa University |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 29 |
|---|
| Number | 4 |
|---|
| Page | 413-433 |
|---|
| Year/Month | 1992/4 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]A multi-center trial of β-methyl-p-(123I)-iodophenyl-pentadecanoic acid (123I-BMIPP) was performed to assess its clinical usefulness in the evaluation of myocardial fatty acid metabolism in 587 patients with various heart diseases. 123I-BMIPP showed relatively decreased uptake compared with 201Tl in the myocardial lesions of 62% of patients with ischemic heart disease (IHD), 39% of those with cardiomyopathy and 32% of those with other heart diseases. In case of myocardial infarction, less uptake of 123I-BMIPP (Type B) than 201Tl was more frequently seen in patients with successful recanalization than in those without recanalization. The patients with matched distribution of the two tracers (Type E) increased in the direct proportion to the interval between the onset of myocardial infarction and the radionuclide studies. The uptake of 123I-BMIPP correlated well with myocardial viability evaluated by 201Tl exercise-redistribution studies. Type B was frequently seen in the areas with 201Tl redistribution, while Type E was seen in the fixed defect areas. In the other heart diseases studied, Type E was observed in approximately 60% of patients with dilated or secondary cardiomyopathies. Type B was seen in about 45% of patients with valvular heart diseases and myocarditis. Various types of mismatch between the two tracers were demonstrated in hypertrophic cardiomyopathy and hypertensive heart disease. It is concluded that 123I-BMIPP is a safe and useful agent for the diagnosis of various heart diseases, since it reflects myocardial fatty acid metabolism. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | β-methyl-p-iodophenyl-pentadecanoic acid (123I-BMIPP), Myocardial fatty acid metabolism, Viability, Phase 3 study, Clinical usefulness. |
|---|